Citations 1
The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.
Tefferi, Ayalew , Gangat, Naseema , Niederwieser, Dietger , Droogenbroeck, Jan Van, Baer, Maria R. , Cervantes, Francisco , Sirhan, Shireen , Langlois, Angélique, Wan, Ying , Sherman, Laurie, Dougherty, Souria, Feller, Faye, Odenike, Olatoyosi , Kiladjian, Jean‐Jacques , Hoffman, Ronald , Finazzi, Guido , Gotlib, Jason , Apperley, Jane F.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7079-TPS7079
